Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction), neprilysin inhibition reduced the risk of cardiovascular death and total hospitalizations by 13%, improved KCCQ by 1.0 points, and had no overall effect on the EuroQol Visual Analog Scale.3,9”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Self-citationThe perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Self-citationSolomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationPhenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and sur- vival times. Appl Stat 2006; 55: 31-9.
Cited by
Items 301–400 of 1,000
Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes
Gulsin, G. S., Henson, J. J., Brady, E. M., Sargeant, J. A., Wilmot, E. G., Athithan, L., Htike, Z. Z., Marsh, A.-M., Biglands, J. D., Kellman, P., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0706 · Cited by 50
“While diastolic dysfunction has long been considered a central mechanism driving HFpEF, the role of microvascular inflammation and endothelial dysfunction is now increasingly being recognized (27).”
InfluentialVerbrugge, F. H., Reddy, Y. N. V., Sorimachi, H., Omote, K., Carter, R. E., & Borlaug, B. A. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2142 · Cited by 51
Phenotyping heart failure using model‐based analysis and physiology‐informed machine learning
Jones, E., Randall, E. B., Hummel, S. L., Cameron, D. M., Beard, D. A., & Carlson, B. E. (2021) · The Journal of Physiology · doi:10.1113/jp281845 · Cited by 52
Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction
Tona, F., Montisci, R., Iop, L., & Civieri, G. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2021.01.277 · Cited by 54
“Based on the promising results in HFrEF, the PARAGON-HF trial [42] analyzed the efficacy in HFpEF of sacubitril-valsartan (LCZ696) compared with val-”
ResultAbdin, A., Böhm, M., Shahim, B., Karlström, P., Kulenthiran, S., Skouri, H. N., & Lund, L. H. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132304 · Cited by 53
Vaduganathan, M., Jhund, P. S., Claggett, B. L., Packer, M., Widimsky, J., Jr., Seferovic, P. M., Rizkala, A. R., Lefkowitz, M. P., Shi, V. C., McMurray, J. J. V., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa184 · Cited by 51
Self-citationHuusko, J., Tuominen, S., Studer, R. L., Corda, S., Proudfoot, C., Lassenius, M. I., & Ukkonen, H. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12792 · Cited by 50
Peng, S., Lu, X., Qi, Y., Li, J., Xu, J., Yuan, T., Wu, X., Ding, Y., Li, W., Zhou, G., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9815039 · Cited by 49
Yan, Y., Liu, B., Du, J. C., Wang, J., Jing, X., Liu, Y., Deng, S., Du, J., & She, Q. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13313 · Cited by 50
“However, ARNI has not demonstrated any significant prevention effects on cardiovascular events in patients with preserved ejection fraction (EF).(8) In heart failure with reduced ejection fraction (HFrEF), ARNI was superior to ACEI in reducing the risk of cardiovascular death or hospitalization for heart failure.”
BackgroundBayés‐Genís, A., Egea, O. I., Spitaleri, G., Domingo, M., Revuelta‐López, E., Codina, P., Cediel, G., Santiago‐Vacas, E., Cserkóová, A., Pascual-Figal, D. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91546-z · Cited by 48
Sex and Gender Bias as a Mechanistic Determinant of Cardiovascular Disease Outcomes
Kim, I., Field, T. S., Wan, D., Humphries, K. H., & Sedlak, T. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.09.009 · Cited by 57
Contributions of Inflammation to Cardiometabolic Heart Failure with Preserved Ejection Fraction
Thorp, E. B., & Filipp, M. E. (2024) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023405 · Cited by 51
CMR Tissue Characterization in Patients with HFmrEF
Doeblin, P., Hashemi, D., Tanacli, R., Lapinskas, T., Gebker, R., Stehning, C., Motzkus, L. A., Blum, M., Tahirović, E., Đorđević, A., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111877 · Cited by 47
“This would be in line with the findings of the PARAGON-HF trial, which showed no overall benefit of angiotensin-neprilysin inhibition in all patients with an LV-EF > 45% but a possible benefit for the subgroup with an LV-EF below the median [26].”
ResultSelf-citationHeart failure and acute renal dysfunction in the cardiorenal syndrome
Chahal, R. S., Chukwu, C., Kalra, P. R., & Kalra, P. A. (2020) · Clinical Medicine · doi:10.7861/clinmed.2019-0422 · Cited by 56
Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF
Jering, K., Zannad, F. M., Claggett, B. L., Causland, F. R. M., Ferreira, J. P., Desai, A. S., Barkoudah, E., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.08.014 · Cited by 48
Self-citationSuzuki, K., Claggett, B. L., Minamisawa, M., Nochioka, K., Mitchell, G. F., Anand, I. S., Zannad, F. M., Shah, S. J., Lefkowitz, M. P., Shi, V. C., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.16277 · Cited by 47
Self-citationBurden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy
Jering, K., Claggett, B. L., Redfield, M. M., Shah, S. J., Anand, I. S., Martínez, F. A., Sabarwal, S. V., Seferovic, P. M., Saraiva, J. F. K., Katova, T., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.01.011 · Cited by 47
Self-citationInhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice
Mishra, S., Hahn, V. S., Sadagopan, N., Dunkerly-Eyring, B. L., Rodriguez, S., Sarver, D. C., Murphy, S. A., Knútsdóttir, H., Knútsdóttir, H., Jani, V., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148798 · Cited by 47
“Lastly, it is worth noting that the combination of sacubitril and valsartan (neprilysin inhibitor and AT-1 receptor blocker) for patients with HFpEF appears to have some efficacy (55) and was approved by the FDA for patients with an ejection fraction of at least 40%.”
BackgroundCurrent status on the therapeutic strategies for heart failure and diabetic cardiomyopathy
Kim, A. H., Jang, J. E., & Han, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112463 · Cited by 51
Chandramouli, C., Ting, T. W., Tromp, J., Agarwal, A., Svedlund, S., Saraste, A., Hage, C., Tan, R., Beussink‐Nelson, L., Fermer, M. L., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2435 · Cited by 50
Self-citationBrain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure
Alcidi, G., Goffredo, G., Correale, M., Brunetti, N. D., & Iacoviello, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113192 · Cited by 51
Inflammation as a therapeutic target in heart failure with preserved ejection fraction
Peh, Z. H., Dihoum, A., Hutton, D. L., Arthur, J. S. C., Rena, G., Khan, F., Lang, C. C., & Mordi, I. R. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1125687 · Cited by 50
“The TOPCAT (4) (spironolactone) and PARAGON-HF (5) (sacubitril/valsartan) trials also failed to meet their primary outcomes, though there were perhaps some positive signals 01 frontiersin.org in specific groups (for example patients recruited in the Americas (6) in TOPCAT and women or those with mildly reduced ejectio…”
BackgroundSex-related differences in the pharmacological treatment of heart failure
Tamargo, J. L., Caballero, R., & Delpón, E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107891 · Cited by 47
Survival analyses in cardiovascular research, part II: statistical methods in challenging situations
Rosselló, X., & González‐Del‐Hoyo, M. (2021) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2021.07.001 · Cited by 60
Codina, P., Domingo, M., Barceló, E., Gastelurrutia, P., Sánchez, D. C., Vila, J., Altisent, O. A., Spitaleri, G., Cediel, G., Santiago‐Vacas, E., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13952 · Cited by 46
Meyer, M., de Lavallaz, J. D. F., Benson, L., Savarese, G., Dahlström, U., & Lund, L. H. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.015 · Cited by 45
Harada, T., Kagami, K., Kato, T., & Obokata, M. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.11.003 · Cited by 46
Sachdev, V., Sharma, K., Keteyian, S. J., Alcain, C. F., Desvigne-Nickens, P. M., Fleg, J. L., Florea, V. G., Franklin, B. A., Guglin, M. E., Halle, M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.012 · Cited by 48
Updates in Cardiorenal Syndrome
McCallum, W. I., & Testani, J. M. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.03.011 · Cited by 52
Current status of heart failure: global and Korea
Park, J. J., & Choi, D. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.120 · Cited by 47
“Similarly, sacubitril/valsartan, an angiotensin-receptor-neprilysin inhibitor, failed to improve survival in patients with HFpEF [39].”
BackgroundResultMarędziak, M., Bengs, S., Portmann, A., Haider, A., Wijnen, W. J., Warnock, G., Etter, D., Fröhlich, S., Fiechter, M., Meisel, A., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04892-x · Cited by 45
“In addition, a 22% higher rate of the clinical endpoint was observed in patients with a higher LVEF ≥ 58% as compared to patients with an LVEF of 45–57% [48].”
Peigh, G., Shah, S. J., & Patel, R. B. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00510-5 · Cited by 45
Self-citationConsensus statement on the current pharmacological prevention and management of heart failure
Sindone, A. P., Pasquale, C. G. D., Amerena, J. V., Burdeniuk, C., Chan, A., Coats, A. J. S., Hare, D. L., Macdonald, P. S., Sverdlov, A. L., & Atherton, J. J. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51656 · Cited by 49
Xiang, B., Zhang, R., Wu, X., & Zhou, X. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31963 · Cited by 52
New aspects in cardiorenal syndrome and HFpEF
Méndez, A. B., Azancot, M. A., Olivella, A., & Soler, M. J. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac133 · Cited by 52
Management of Heart Failure in Patients with Chronic Kidney Disease
Ryan, D. K., Banerjee, D., & Jouhra, F. (2022) · European Cardiology Review · doi:10.15420/ecr.2021.33 · Cited by 53
Phosphodiesterase in heart and vessels: from physiology to diseases
Fu, Q., Wang, Y., Chen, Y., & Xiang, Y. K. (2023) · Physiological Reviews · doi:10.1152/physrev.00015.2023 · Cited by 50
Gu, J., Pan, J., Lin, H., Zhang, J., & Wang, C. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.065 · Cited by 46
Pulmonary hypertension in aortic valve stenosis
Maeder, M. T., Weber, L., & Rickli, H. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.12.005 · Cited by 48
Wijkman, M. O., Claggett, B. L., Vaduganathan, M., Cunningham, J. W., Rørth, R., Jackson, A. M., Packer, M., Zile, M. R., Rouleau, J. L., Swedberg, K. B., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01545-1 · Cited by 49
“The primary and secondary outcomes of the PARA-GON-HF trial have been published previously [11].”
Self-citationSacubitril/Valsartan in Heart Failure: Efficacy and Safety in and Outside Clinical Trials
Abdin, A., Schulz, M., Riemer, U., Hadëri, B., Wachter, R., Laufs, U., Bauersachs, J. K., Kindermann, I., Vukadinović, D., & Böhm, M. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14097 · Cited by 51
Minh, H. V., Huy, T. V., Doan, L., & Tien, H. A. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14580 · Cited by 58
Wachter, R., Shah, S. J., Cowie, M., Szecsödy, P., Shi, V. C., Ibram, G., Zhao, Z., Gong, J., Klebs, S. H. G., & Pieske, B. M. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12694 · Cited by 47
Self-citationGut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?
Belli, M., Barone, L., Longo, S., Prandi, F. R., Lecis, D., Mollace, R., Margonato, D., Muscoli, S., Sergi, D., Federici, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511971 · Cited by 47
Updates on New Therapies for Patients with CKD
Tarun, T., Ghanta, S. N., Ong, V., Kore, R. A., Menon, L., Kovesdy, C. P., Mehta, J. L., & Jain, N. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.10.006 · Cited by 49
“…of angiotensin receptor-neprilysin inhibitor with angiotensin-receptor blockers Global Outcomes in Heart Failure with preserved ejection fraction) trial (Supplementary Table S1) 57 ; both RCTs reporting reduced CV-death and HF admissions by 25% to 30% with ARNI over ACEi or ARB monotherapy.”
BackgroundInfluentialRole of Kinins in Hypertension and Heart Failure
Hamid, S., Rhaleb, I. A., Kassem, K. M., & Rhaleb, N. (2020) · Pharmaceuticals · doi:10.3390/ph13110347 · Cited by 44
Vaduganathan, M., Cunningham, J. W., Claggett, B. L., Causland, F. M., Barkoudah, E., Finn, P. V., Zannad, F. M., Pfeffer, M. A., Rizkala, A. R., Sabarwal, S. V., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.01.014 · Cited by 47
Self-citationBai, B., Cheng, M., Jiang, L., Xu, J., Chen, H., & Xu, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.614757 · Cited by 46
“In contrast to positive outcomes in heart failure with reduced ejection fraction (HFrEF) treated by neurohumoral inhibition, most of the large-scale clinical trials to assess the efficiency of medical therapies for HFpEF have not shown positive results yet (2, 3).”
BackgroundResultDesai, A. S., Vaduganathan, M., Cleland, J. G. F., Claggett, B. L., Barkoudah, E., Finn, P., McCausland, F. R., Yilmaz, M. B., Lefkowitz, M. P., Shi, V. C., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008597 · Cited by 43
Self-citationAdvances in the Treatment Strategies in Hypertension: Present and Future
Verdecchia, P., Cavallini, C., & Angeli, F. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9030072 · Cited by 51
“In contrast, LCZ696, a more recently developed combination of neprilysin with the angiotensin II receptor blocker valsartan in the same molecule, proved effective and well tolerated in heart failure [61,62] and hypertension [63].”
BackgroundRecent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines
Tsutsui, H. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108185 · Cited by 47
Acute Heart Failure After Non-Cardiac Surgery: Incidence, Phenotypes, Determinants and Outcomes
Gualandro, D. M., Puelacher, C., Chew, M. S., Andersson, H., Buse, G. L., Glarner, N., Mueller, D., Cardozo, F. A. M., Burri‐Winkler, K., Mork, C., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2773 · Cited by 44
Mohammed, A., Luo, Y., Wang, K., Su, Y., Liu, L., Yin, G., Zhang, W., Alifu, J., Mareai, R. M., Mohammed, A. A. S., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02157-7 · Cited by 46
“HFpEF persists as an unaddressed clinical demand, representing a multifaceted complex entity associated with a dire prognosis and substantial healthcare costs [5, 6].”
BackgroundSattar, N. A., Butler, J., Lee, M. M. Y., Harrington, J., Sharma, A., Zannad, F. M., Filippatos, G. S., Verma, S., Januzzi, J. L., Ferreira, J. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3221 · Cited by 44
Self-citationNetwork medicine in Cardiovascular Research
Lee, L. Y.-H., Pandey, A. K., Maron, B. A., & Loscalzo, J. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa321 · Cited by 47
“92) per 10% decline in LVEF].(120) While further mechanistic studies are needed to explain these”
BackgroundInfluentialSotomi, Y., Iwakura, K., Hikoso, S., Inoue, K., Onishi, T., Okada, M., Fujii, K., Okamura, A., Tamaki, S., Yano, M., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13302 · Cited by 42
Akasaka, H., Sugimoto, K., Shintani, A., Taniuchi, S., Yamamoto, K. I., Iwakura, K., Okamura, A., Takiuchi, S., Fukuda, M., Kamide, K., et al. (2022) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14363 · Cited by 41
Ohte, N., Kikuchi, S., Iwahashi, N., Kinugasa, Y., Dohi, K., Takase, H., Masai, K., Inoue, K., Okumura, T., Hachiya, K., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac240 · Cited by 41
Prausmüller, S., Weidenhammer, A., Heitzinger, G., Spinka, G., Goliasch, G., Arfsten, H., Mawgoud, R. A., Gabler, C., Strunk, G., Hengstenberg, C., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad140 · Cited by 43
C-type natriuretic peptide moderates titin-based cardiomyocyte stiffness
Michel, K., Herwig, M., Werner, F., Spes, K. Š., Abeßer, M., Schuh, K., Dabral, S., Mügge, A., Baba, H. A., Skryabin, B. V., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.139910 · Cited by 43
“41) the results of the here-presented focused experimental studies suggest that correction or augmentation of CNP/titin signaling may moderate pathological myocardial wall stiffness and improve diastolic function at earlier or less severe disease stages.”
Maffeis, C., Morris, D. A., Belyavskiy, E., Kropf, M., Radhakrishnan, A. K., Zach, V., da Conceicao, C. R., Trippel, T. D., Pieske‐Kraigher, E., Rossi, A., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13143 · Cited by 41
Self-citationJaiswal, A., Jaiswal, V., Ang, S. P., Hanif, M., Vadhera, A., Agrawal, V., Kumar, T., Nair, A. M., Borra, V., Garimella, V., et al. (2023) · Medicine · doi:10.1097/md.0000000000034693 · Cited by 43
“[5] It is accompanied by comorbidities (such as obesity) that do not lead to marked ventricular enlargement.”
BackgroundWinkle, P. J., Goldsmith, S. R., Koren, M. J., Lepage, S., Hellawell, J. L., Trivedi, A., Tsirtsonis, K., Abbasi, S. A., Kaufman, A., Troughton, R. W., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07328-w · Cited by 40
Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach
Sukumar, S., Orkaby, A. R., Schwartz, J. B., Marcum, Z. A., Januzzi, J. L., Vaduganathan, M., & Warraich, H. J. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00559-w · Cited by 41
Saito, Y., Obokata, M., Harada, T., Kagami, K., Wada, N., Okumura, Y., & Ishii, H. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad127 · Cited by 40
Zhang, Z., Wang, C., Tu, T., Lin, Q., Zhou, J., Huang, Y., Wu, K., Zhang, Z., Zuo, W., Liu, N., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00646-4 · Cited by 43
“Similarly, the PARAGON-HF trial revealed that ARNIs could reduce the risk of combined endpoint events, including HF hospitalization and cardiovascular death, by 21% in patients with an eGFR 60 ml/min/1.73 2 [48].”
MethodInfluentialSelf-citationMark, P. B., Mangion, K., Rankin, A. J., Rutherford, E., Lang, N. N., Petrie, M. C., Stoumpos, S., & Patel, R. K. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac146 · Cited by 46
“PARAGON-HF [107] HF and LVEF ≥ 45% and eGFR > 30 mL/min/1.”
BackgroundInfluentialDocherty, K. F., Bayés‐Genís, A., Butler, J., Coats, A. J. S., Drazner, M. H., Joyce, E., & Lam, C. S. P. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac113 · Cited by 45
“A prespecified subgroup analysis by LVEF ≤ or > than the median (57%) suggested a greater benefit in those with a lower LVEF, with a similar differential effect observed when stratified by sex, with a greater benefit seen in women.(16,29) In an analysis combining the PARADIGM-HF and PARAGON-HF cohorts (i.”
MethodSelf-citationPacker, M., Zannad, F. M., & Anker, S. D. (2021) · Circulation · doi:10.1161/circulationaha.121.056657 · Cited by 40
Self-citationReappraisal on pharmacological and mechanical treatments of heart failure
Liang, B., Zhao, Y.-X., Zhang, X., Liao, H.-L., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01024-5 · Cited by 40
“[17] , CARVIVA HF [18] Sacubitril/valsartan PARADIGM-HF [19] [20] [21] [22] [23] , PIONEER-HF [24, 25] , EVALUATE-HF [26] , TRANSITION [27, 28] , PARAMOUNT [29, 30] , PARAGON-HF [31] Nebivolol SENIORS [33] [34] [35] [36] [37] , Sessa et al.”
BackgroundMethodInfluentialCroteau, D., Qin, F., Chambers, J. M., Kallick, E., Luptak, I., Panagia, M., Pimentel, D. R., Siwik, D. A., & Colucci, W. S. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.07.006 · Cited by 42
“In the PARAGON (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction) trial, which was performed in patients with HFpEF of diverse etiologies and phenotypes, SAC/VAL did not meet the primary endpoint of hospitalization for heart fail…”
BackgroundZhang, H., Huang, T., Shen, W., Xu, X., Yang, P., Zhu, D., Fang, H., Wan, H., Wu, T., Wu, Y., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12974 · Cited by 42
“048) in the PARAGON‐HF study.(13) However, regarding the rate of serious hyperkalaemia (≥6.”
BackgroundResultThe PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
Gronda, E., Vanoli, E., & Iacoviello, M. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa140 · Cited by 43
Nielsen, E. E., Feinberg, J. B., Bu, F.-L., Olsen, M. H., Raymond, I. E., Steensgaard-Hansen, F., & Jakobsen, J. C. (2020) · Open Heart · doi:10.1136/openhrt-2020-001294 · Cited by 41
Mitochondrial function, dynamics and quality control in the pathophysiology of HFpEF
del Campo, A., Perez, G., Castro, P., Parra, V., & Verdejo, H. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166208 · Cited by 41
ARNI Versus ACEI/ARB in Reducing Cardiovascular Outcomes After Myocardial Infarction
She, J., Lou, B., Liu, H., Zhou, B., Jiang, G. T., Luo, Y., Wu, H., Wang, C., & Yuan, Z. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13644 · Cited by 41
Sotomi, Y., Hikoso, S., Nakatani, D., Okada, K., Dohi, T., Sunaga, A., Kida, H., Sato, T., Matsuoka, Y., Kitamura, T., et al. (2023) · Heart · doi:10.1136/heartjnl-2022-322181 · Cited by 40
Mentz, R. J., Brunton, S., & Rangaswami, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02023-y · Cited by 41
The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?
Cinti, F., Laborante, R., Cappannoli, L., Morciano, C., Gugliandolo, S., Pontecorvi, A., Burzotta, F., Donniacuo, M., Cappetta, D., Patti, G., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02767-9 · Cited by 44
“…in large randomized clinical trials in HFpEF, including renin-angiotensin-aldosterone system (RAAS) inhibitors, mineralocorticoid-receptor antagonists, digoxin and the most recent valsartan/sacubitril, were successful in reducing the incidence of major adverse cardiovascular events [119–124].”
Heart Failure With Mid-range Ejection Fraction
Srivastava, P. K., Hsu, J. J., Ziaeian, B., & Fonarow, G. C. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-019-00451-0 · Cited by 43
Heart failure with preserved ejection fraction: Similarities and differences between women and men
Pepine, C. J., Merz, C. N. B., Hajj, S. C. E., Ferdinand, K. C., Hamilton, M. A., Lindley, K. J., Nelson, M. D., Quesada, O., WENGER, N. K., & Fleg, J. L. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.01.003 · Cited by 41
Kuno, T., Ueyama, H. A., Fujisaki, T., Briasouli, A. A., Takagi, H., & Briasoulis, Α. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.01.009 · Cited by 42
Asymptomatic Left Ventricle Systolic Dysfunction
Sara, J. D. S., Toya, T., Taher, R., Lerman, A., Gersh, B. J., & Anavekar, N. S. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.14 · Cited by 40
“However, lower LVEF was associated with a reduction in HF hospitalisation and cardiovascular death in this population, indicating the potential benefit of sacubitril–valsartan in patients with more severe LVEF reduction.(61) Further trials, including contemporary populations and therapeutics, are required to determine…”
BackgroundThe Role of Arterial Stiffness and Central Hemodynamics in Heart Failure
Weber, T. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0029 · Cited by 38
Ueda, T., Kasama, S., Yamamoto, M., Nakano, T., Ueshima, K., Morikawa, Y., Kawata, H., Yoshihisa, A., Nakayama, M., Komatsu, S., et al. (2021) · Circulation Reports · doi:10.1253/circrep.cr-21-0030 · Cited by 44
Shahim, A., Hourqueig, M., Donal, E., Oger, E., Venkateshvaran, A., Daubert, J., Savarese, G., Linde, C. M., Lund, L. H., & Hage, C. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13533 · Cited by 43
Mecinaj, A., Gulati, G., Heck, S. L., Holte, E., Fagerland, M. W., Larsen, A. I., Blix, E. S., Geisler, J., Wethal, T., & Omland, T. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00115-w · Cited by 38
“Subgroup analyses of patients with chronic heart failure and preserved ejection fraction in the PARAGON (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF) trial suggest that patients with heart failure and mild reduction in LVEF may benefit…”
BackgroundLeft Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
Dimond, M. G., Ibrahim, N. E., Fiuzat, M., McMurray, J. J. V., Lindenfeld, J. M., Ahmad, T., Bozkurt, B., Bristow, M. R., Butler, J., Carson, P. E., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.11.005 · Cited by 41
Self-citationSacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow, D. A., Velazquez, E. J., Desai, A. S., DeVore, A. D., Lepage, S., Park, J., Sharma, K., Solomon, S. D., Starling, R. C., Ward, J. H., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.027 · Cited by 43
Self-citationMineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function
Matsumoto, S., Henderson, A. D., Shen, L., Yang, M., Swedberg, K. B., Vaduganathan, M., van Veldhuisen, D. J., Solomon, S. D., Pitt, B., Zannad, F. M., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.426 · Cited by 42
Self-citationHeart failure with reduced and preserved ejection fraction in adult congenital heart disease
Vaikunth, S. S., & Lui, G. K. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09904-z · Cited by 40
“Similarly, the PARAGON-HF trial of sacubitril/valsartan did not improve rate of hospitalizations or cardiovascular death [109].”
MethodAssociation of Left Ventricular Systolic Function With Incident Heart Failure in Late Life
Jensen, A. M. R., Zierath, R., Claggett, B. L., Skali, H., Solomon, S. D., Matsushita, K., Konety, S., Butler, K. R., Kitzman, D. W., Biering‐Sørensen, T., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.0131 · Cited by 37
Self-citationVaduganathan, M., Claggett, B. L., Greene, S. J., Aggarwal, R., Bhatt, A. S., McMurray, J. J. V., Fonarow, G. C., & Solomon, S. D. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.3651 · Cited by 37
Self-citationThe Role of Systemic Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction
Weerts, J., Mourmans, S. G. J., Aizpurua, A. B., Schroen, B. L. M., Knackstedt, C., Eringa, E. C., Houben, A. J. H. M., & van Empel, V. P. M. (2022) · Biomolecules · doi:10.3390/biom12020278 · Cited by 40
The Challenges of NT-proBNP Testing in HFpEF
Januzzi, J. L., & Myhre, P. L. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.03.003 · Cited by 37
Adejumo, P., Thangaraj, P. M., Dhingra, L. S., Aminorroaya, A., Zhou, X., Brandt, C., Xu, H., Krumholz, H. M., & Khera, R. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.43925 · Cited by 36
Cho, J. Y., Cho, D., Youn, J., Kim, D., Park, S. M., Jung, M., Hyun, J., Choi, J., Cho, H., Park, S., et al. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0009 · Cited by 37
Desai, N. R., Olewińska, E., Famulska, A., Rémuzat, C., François, C., & Folkerts, K. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10385-y · Cited by 41
“A higher percentage of patients in the sacubitril/valsartan group than in the valsartan group had an improvement of ≥ 5 points in their KCCQ clinical summary score (33.0% vs 29.6%; OR: 1.30; 95% CI, 1.04–1.61) [ 85].”
BackgroundMethodInfluentialFeng, Y., Yin, Y., Deng, R., & Li, H. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13243 · Cited by 38
Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions
Galo, J., Celli, D. A., & Colombo, R. A. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00445-7 · Cited by 36
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., Comin-Colet, J., Cleland, J., Düngen, H.-D., Goncalvesova, E., Katova, T., Kerr Saraiva, J. F., Lelonek, M., Merkely, B., Senni, M., Shah, S. J., Zhou, J., Rizkala, A. R., Gong, J., Shi, V. C., & Lefkowitz, M. P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Anand, Inder S.
- Ge, Junbo
- Lam, Carolyn S.P.
- Maggioni, Aldo P.
- Packer, Milton
- Pfeffer, Marc A.
- Pieske, Burkert
- Redfield, Margaret M.
- Rouleau, Jean L.
- Zannad, Faiez
- Zile, Michael R.
- Desai, Akshay S.
- Claggett, Brian
- Jhund, Pardeep S.
- Boytsov, Sergey A.
- Cleland, John
- Düngen, Hans-Dirk
- Lelonek, Małgorzata
- Senni, Michele
- Shah, Sanjiv J.
- Zhou, Jingmin
- Rizkala, Adel R.
- Gong, Jianjian
- Shi, Victor C.
- Lefkowitz, Martin P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1609-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971294569
- Cited by
- 2,430
- References
- 25
- Citations by year
- 2026: 258 · 2025: 296 · 2024: 338 · 2023: 361 · 2022: 414 · 2021: 385 · 2020: 318 · 2019: 55
- FWCI
- 211.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- sacubitril/valsartan, valsartan, angiotensin receptor-neprilysin inhibition, heart failure with preserved ejection fraction, heart failure hospitalization, cardiovascular mortality, NYHA functional class, renal function, Kansas City Cardiomyopathy Questionnaire, natriuretic peptides, structural heart disease, drug safety, adverse events, anemia of chronic kidney disease, hyperkalemia
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angioedema, Biphenyl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Quality of Life, Sex Factors, Stroke Volume, Tetrazoles, Neprilysin, Single-Blind Method, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.